Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Beth Marsh. Image credit: Neurotech Pharmaceuticals.

Beth Marsh is stepping into the role of chief commercial officer (CCO) at Neurotech Pharmaceuticals, beginning 28 April, the company announced in a press release. Marsh will lead the organisation, particularly as it prepares for the US launch of revakinagene taroretcel-lwey (ENCELTO), approved for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

Richard Small, chief executive officer of Neurotech, commmented on the appointment, saying, “I am confident that [Marsh’s] expertise in launching new therapies that address unmet needs, and her extensive network of leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch."

Marsh comes to Neurotech with more than two decades of leadership and expertise in ophthalmology and retina. Most recently, she served as Apellis Pharmaceuticals’ vice president, North America sales and marketing in ophthalmology. There, she led the company’s US commercial launch of pegcetacoplan (SYFOVRE) for the treatment of geographic atrophy secondary to age-related macular degeneration.

Marsh also previously served as the global product strategy lead of ophthalmology at Shire/Takeda Pharmaceuticals. In her early career, she served in commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care and Santen. Marsh's professional background includes serving as a volunteer and as past president of Ophthalmic World Leaders (OWL): Advancing diversity in leadership in ophthalmology.

“This is an important and transformative time to join Neurotech as the company prepares for commercialisation of the first and only approved treatment for adults suffering with MacTel,” Marsh said.

The US Food and Drug Administration (FDA) approved revakinagene taroretcel-lwey (ENCELTO) in March. At the date of approval, revakinagene taroretcel-lwey is the first and only FDA-approved treatment for MacTel, utilising an encapsulated cell therapy (ECT) technology designed to continually deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina, assisting in slowing the progression of the disease.

Reference:

1. Neurotech Appoints Beth Marsh as Chief Commercial Officer.; 2025. Accessed April 21, 2025. https://www.neurotechpharmaceuticals.com/wp-content/uploads/Neurotech_Press-Release_Chief-Commercial-Officer_FINAL.pdf

2. Harp MD, Hayes H. FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2. Modern Retina. Published March 6, 2025. Accessed April 21, 2025. https://www.modernretina.com/view/fda-approves-revakinagene-taroretcel-lwey-encelto-for-macular-telangiectasia-type-2